Literature DB >> 10613332

CT-based dosimetry calculations for 125I prostate implants.

J J DeMarco1, J B Smathers, C M Burnison, Q K Ncube, T D Solberg.   

Abstract

PURPOSE: To evaluate the Monte Carlo code MCNP4B for low-energy brachytherapy calculations, including the effects of interseed attenuation and patient specific heterogeneities, on the calculated dose distribution from transperineal implantation of 125I. METHODS AND MATERIALS: The Monte Carlo code MCNP4B was used to model and benchmark the absolute dose distribution from two 125I brachytherapy seeds (model 6711 and 6702). Based upon the physical source model, the total photon intensity and differential energy spectrum were evaluated as a function of angle from the transverse bisector of the source. These spectral and intensity data were reformatted to produce probability distributions for sampling from a virtual point source. The virtual source model and a modified version of MCNP4B is then used for simulating arbitrary brachytherapy source configurations within a homogeneous or heterogeneous patient specific computed tomography (CT)-based lattice geometry. RESULTS AND
CONCLUSION: Comparison with TG-43 data and the Monte Carlo calculations is excellent with MCNP4B predicting the radial dose function for the 125I 6711 and 6702 sources within 6% for all data points tested. Attenuation effects from neighboring seeds were investigated for pre- and postimplant seed distributions and found to be negligible. Preliminary dosimetry analysis of postimplant seed distributions comparing homogeneous water versus heterogeneous CT simulation geometries indicates an average decrease of approximately 5.6% for the volume of tissue irradiated to a prescription isodose line of 144 Gy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10613332     DOI: 10.1016/s0360-3016(99)00343-0

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  5 in total

1.  AAPM recommendations on dose prescription and reporting methods for permanent interstitial brachytherapy for prostate cancer: report of Task Group 137.

Authors:  Ravinder Nath; William S Bice; Wayne M Butler; Zhe Chen; Ali S Meigooni; Vrinda Narayana; Mark J Rivard; Yan Yu
Journal:  Med Phys       Date:  2009-11       Impact factor: 4.071

2.  Dosimetric effect of tissue heterogeneity for (125)I prostate implants.

Authors:  Susana Maria Oliveira; Nuno José Teixeira; Lisete Fernandes; Pedro Teles; Pedro Vaz
Journal:  Rep Pract Oncol Radiother       Date:  2014-04-16

3.  Fast patient-specific Monte Carlo brachytherapy dose calculations via the correlated sampling variance reduction technique.

Authors:  Andrew Sampson; Yi Le; Jeffrey F Williamson
Journal:  Med Phys       Date:  2012-02       Impact factor: 4.071

4.  Dosimetric parameters of three new solid core I-125 brachytherapy sources.

Authors:  Timothy D Solberg; John J DeMarco; Geoffrey Hugo; Robert E Wallace
Journal:  J Appl Clin Med Phys       Date:  2002       Impact factor: 2.102

Review 5.  Review of clinical brachytherapy uncertainties: analysis guidelines of GEC-ESTRO and the AAPM.

Authors:  Christian Kirisits; Mark J Rivard; Dimos Baltas; Facundo Ballester; Marisol De Brabandere; Rob van der Laarse; Yury Niatsetski; Panagiotis Papagiannis; Taran Paulsen Hellebust; Jose Perez-Calatayud; Kari Tanderup; Jack L M Venselaar; Frank-André Siebert
Journal:  Radiother Oncol       Date:  2013-11-30       Impact factor: 6.280

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.